Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data

Abstract: Recent advances in the understanding of the pathophysiology of ulcerative colitis (UC) have led to the expansion of our therapeutic arsenal. Conventional treatment options, including aminosalicylates, corticosteroids, thiopurines, and calcineurin inhibitors, fail to control the disease in a significant proportion of patients. Approximately 25–50% of the patients treated with tumor necrosis factor antibodies (anti-TNFα) are primary and secondary non-responders to therapy. Tofacitinib is a novel orally administered small synthetic molecule that inhibits a homologous family of enzymes, termed Janus kinases that modulate multiple key cytokines involved in the pathogenesis of UC. Phase II and III trials showed promising results in UC, leading to the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to approve its administration for the induction and maintenance of remission in moderate-to-severe UC. Herein, we review tofacitinib for the management of UC, its mechanism of action pharmacokinetic properties, efficacy, and safety.

Keywords: tofacitinib, ulcerative colitis, Janus kinase inhibitors, Jaksibns

Introduction

Ulcerative colitis (UC) is an idiopathic immune-mediated inflammatory bowel disease of the colon. It is often diagnosed in the third and fourth decades of life and leads to significant mortality and morbidity. Both UC and Crohn’s disease are associated with economic impact from hospitalization and surgery and also loss of productivity at work. More than 80% of the UC patients run a relapsing disease course, whereas 10–15% experience an aggressive course. In 30% of the patients, the disease distribution is left-sided. Symptoms of UC include diarrhea, rectal bleeding, urgency, tenesmus, and fecal incontinence. Patients with UC are at risk of dysplasia and cancer. Between 10% and 15% undergo colectomy to manage disease or its complications.

Current medical treatment includes aminosalicylates, corticosteroids, thiopurines, and calcineurin inhibitors. Anti-TNFα antibodies are available, but contraindications, primary non-response, loss of response, and intolerance often occur.

In addition to TNFα, there are several other cytokine pathways involved in the development of UC. The IL-23/IL-17 axis is important in human IBD, with elevated Th17 cytokines in human IBD. TGFβ-deficient mice develop severe multi-organ lymphoproliferative disease. IL-10-deficient mice develop spontaneous colitis. The discovery of specific pathways involved in IBD has led to more specific medications targeting these, e.g., ustekinumab targeting the p40 subunit shared between IL12 and IL23. UC is, however, most likely a heterogeneous condition,
with multiple different immune pathways involved in an individual resulting in a common phenotype – therefore, suppression of more than one cytokine pathway may be beneficial.

Tofacitinib (XELJANZ/XELJANZ XR; Pfizer, NY, USA) is an oral small molecule pan-Janus kinase (JAK) inhibitor (molecular weight 312.4 Da; 504.5 for the citrate salt). This is the first oral formulation for the treatment of UC; tofacitinib is less immunogenic than the larger biologic antibodies, has a shorter half life, and has therefore got the advantage of allowing rapid discontinuation in cases of adverse events.

The JAKs are the downstream signaling molecules of a large number of the cytokine pathways involved in IBD. When a cytokine binds its cell surface receptors, it dimerizes the ligand receptors and this results in phosphorylation of the JAK molecules. JAK then activates signal transducer and activator of transcription molecules (STATs), the phosphorylation of which results in STAT migration to the nucleus and activation of gene transcription. By targeting JAK signaling, it is possible to affect multiple cytokine pathways thought to be involved in colitis.

Tofacitinib had been initially approved for the treatment of moderate-to-severe rheumatoid arthritis (RA) [2012] and psoriatic arthritis (PsA) [2017] in adult patients with inadequate response or intolerance to prior disease-modifying antirheumatic drug therapies. Phase II and phase III trials showed promising results in UC, leading the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to approve tofacitinib for the induction and maintenance of remission in moderate-to-severe UC. For induction, 10 mg is given orally twice daily for 8-week period, followed by a maintenance dose of 5 mg twice daily. Nevertheless, in case of inadequate response by week 8, the dose of 10 mg can be extended for another 8 weeks (16 weeks total) prior to attempting dose reduction or can be maintained at 10 mg in those patients who had previously failed anti-TNFα. We review the pharmacokinetic properties, efficacy, and safety of tofacitinib in UC.

Search Strategy

Medline, PubMed, and Scopus search were undertaken by two of the authors (G.M and K.A). The search criteria used were “JAK inhibitor”, “tofacitinib”, “CP-690 550”, “Ulcerative colitis”, “pharmacokinetic”, “side effects”, “adverse events”, and “complications”. A manual search of the clinical trial register, article reference lists, abstracts from Digestive Disease Week, United European Gastroenterology Week, and European Crohn’s Colitis Organization congresses were also conducted up to the 17th of May 2019. After an initial title screen, each relevant article was subsequently reviewed.

Overview of JAKs

JAKs compose a family of tyrosine kinases, that includes four large peptide members (≥1100 amino acids/molecular mass: 120–140 kilodaltons), named JAK 1, JAK 2, JAK 3, and Tyrosine Kinase 2 (TYK-2). Of the four family members, JAK1, JAK2, and TyK2 are ubiquitously expressed, whereas JAK3 is preferentially expressed in hematopoietic cells. All family members have an evolutionary conserved structure, which encompasses the catalytically active and inactive functions of the enzymes and are associated with the different chains of type I/II cytokine receptors intracellularly. A large group of cytokines, including those involved in the pathogenesis of UC, employ type I and II transmembrane receptors that rely on JAKs for intracellular signaling. JAK1 and JAK3 are downstream of cytokine receptors containing the IL-2 receptor common γ chain (e.g., IL-2, IL-4, IL-7, IL-9, IL-15, IL-21), while JAK2 transduce signals from the cytokines binding to hematopoietic growth factor and gp40-containing cytokine receptors. At least two homologous (e.g., JAK2/JAK2) or heterologous (e.g., JAK1/JAK3) JAK molecules are required from each receptor in order to signal. Cytokine binding to the receptor leads to JAK activation, auto-phosphorylation, and phosphorylation. This interaction forms specific binding sites, recruits one or more members of a family of transcription factors, termed STAT (Signal Transducer and Activator of Transcription) proteins, and induces their subsequent phosphorylation. Once activated, STATs dissociate from the receptor and form homo- or hetero-dimers and translocate to the nucleus, where they bind to DNA sequences, and influence gene expression as demonstrated in Figure 1.

JAKs regulate a variety of cytokine-mediated processes including hematopoiesis, inflammation, innate, and adaptive immunity. Aberrant activation of JAKs peptides has been shown to lead either directly or indirectly to a variety of autoimmune and inflammatory disorders, including UC. Hence, it is of no surprise that the pharmacological inhibition of JAK has gained significant attention as a therapeutic target in immune-mediated disorders, with recent genome-wide association studies supporting the rationale of targeting JAKs in UC. The JAK cytokines, however, are not responsible for all cytokine signaling. For example, TNFα mediates gene expression through the NF-kB, JUN kinase, p38 MAPK, and ERK1/ERK2 pathways.
JAK Inhibition and Tofacitinib: Mechanism of Action

Tofacitinib (CP-690, 550) was one of the first JAK inhibitors investigated. After demonstrating significant immunosuppressive effects in pre-clinical animal models of transplantation and arthritis, tofacitinib entered clinical trials in patients with RA. Tofacitinib has undergone further assessment in various other immune-mediated conditions, including PsA and UC.

In order to exert its pharmacologic action, tofacitinib diffuses intracellularly, and then binds to the adenosine triphosphate (ATP) binding site in the catalytic cleft of the kinase domain of JAKs. This action inhibits JAK’s subsequent phosphorylation and STAT activation, and attenuates downstream cytokine production with a consequent downregulation of the immune response.

Tofacitinib is a pan-JAK inhibitor. Although in vitro studies suggested that tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent TYK2 in human cells, in vivo studies have demonstrated it preferentially inhibits JAK1 and JAK3 pathways. As a result, tofacitinib was shown to disrupt to greater extent signaling from JAK3- and JAK1-dependent cytokines (e.g., IL-2, IL-6, interferons [IFN], IL-12, IL-4, IL-7, IL-15, and IL-21), affecting lymphocyte activation, proliferation, and function that are crucial for multiple aspects of the immuno-inflammatory response observed in UC.

Pharmacokinetic Profile

The pharmacokinetic (PK) profile of tofacitinib has been studied in healthy volunteers and in patients with RA, PsA, and UC.

In healthy volunteers, tofacitinib’s time to serum peak concentrations is between 0.5 and 1 hrs, and it is eliminated in 3 hrs. No correlation was observed between dosage and lymphocyte subsets in healthy volunteers. In UC, plasma tofacitinib concentrations increased proportionally with dose and steady-state levels did not change between baseline and 8 weeks. Steady-state concentrations did not differ according to disease activity neither in UC nor in psoriatic arthropathy.

The majority (70%) of the drug is cleared by the liver, with 30% being renally excreted. The clearance of tofacitinib is mediated by cytochrome P450 (CYP) 3A4; however, it does not affect the clearance of other drugs metabolized by CYP enzymes. Use of other drugs that inhibit CYP 34A systems such as fluconazole and ketoconazole increased the half-life of tofacitinib by an hour. This would suggest that some dosage adjustment is required in the context of concomitant CYP34A inhibitor usage. CrCl also affects the half-life of tofacitinib.

Population PK analysis from 1096 UC patients with moderate-to-severe disease activity, pooled across one phase 2 and three phase 3 studies, revealed comparable
PK properties for tofacitinib with those observed in other immune-mediated conditions such as PsA and RA. Based on this comparability, all proposed dosing adjustment recommendations derived from phase 1 studies in RA are also applicable to UC patients. Consequently, in UC patients with moderate renal (defined as creatinine clearance values less than 60 mL/min), it is suggested to reduce to dose of tofacitinib by half. In contrast, no dose modification has been shown to be required for tofacitinib in association with a variety of other patient- and disease-related factors including age, body weight, sex, ethnicity, and baseline disease severity (e.g., baseline Mayo score and baseline albumin). Tofacitinib has not been studied in the context of severe hepatic impairment.  

**Therapeutic Efficacy of Tofacitinib in UC**

A summary of the market-authorizing trials of tofacitinib’s in UC included in this review is shown in Table 1.

**Phase II Studies**

Sandborn et al investigated tofacitinib in a multi-center, double-blinded, randomized controlled trial over an 8-week period for moderate-to-severe UC. 38 Patients were assigned to placebo administered twice daily or tofacitinib (at doses of 0.5, 3, 10, or 15 mg twice daily). The primary endpoint was clinical response (a decrease from baseline total Mayo score by at least 3 points and a relative decrease by at least 30%) at the end of the 8-week period. The secondary endpoint was clinical remission defined as a total Mayo score of 0 to 2.

At 8 weeks, clinical response was observed in 32%, 48%, 61%, and 78% of the patients receiving tofacitinib at doses 0.5, 3, 10, and 15 mg BD, respectively (p values 0.39, 0.55, 0.10, and <0.001), compared with 42% of the patients receiving placebo. Endoscopic response was observed in 52%, 58%, 67%, and 78% of the patients on tofacitinib at doses of 0.5, 3, 10 and 15 mg BD, respectively, compared to 46% of the placebo (p values 0.64, 0.30, 0.07, and 0.001).

Although its highest efficacy was shown to be expected from doses ≥ 10 mg twice daily, safety concerns (dose-dependent hyperlipidemia and viral infections) that have arisen from patients with RA receiving more than 15 mg BD 39 has led the FDA to select the 10 mg dose for the subsequent clinical development of tofacitinib in UC. 38

**Efficacy in Phase III Trials**

**Induction of Remission and Mucosal Healing**

The efficacy of tofacitinib in the induction of remission in patients with moderately-to-severely active UC was investigated in two multi-center, double-blind, placebo-controlled phase 3 trials, named OCTAVE (Oral Clinical Trials for tofACitinib in ulcerative colitis) Induction 1 and 2. 40 In these trials, 1139 eligible patients were randomized (4:1) to receive tofacitinib 10 mg or placebo twice a day for an 8-week period. The patients had moderately-to-severely active (mean total Mayo score: 9) extensive colitis (52%) with a median disease duration of 6 years, mean age of 41 years, with 59% of the participants being male and 80% caucasian. Approximately 70% of the patients had previously failed immunosuppressants other than biologic agents or corticosteroids, 52% had failed treatment with anti-TNFα (56% primary non-responders), and 46% were taking oral corticosteroids upon entry. Aminosalicylates or prednisolone up to 25 mg OD was allowed over the treatment period, but no immunomodulators or biologic therapies. The primary endpoint was clinical remission at 8 weeks (defined as a total Mayo score ≤ 2 points, no individual subscore > 1, rectal bleeding subscore of 0). The key secondary endpoint was mucosal healing (MH defined as endoscopic subscore of 0 or 1) at 8 weeks. Clinical remission at 8 weeks occurred in 19% and 17% of the tofacitinib group, whereas the placebo groups had a remission rate of 8% and 4% in OCTAVE Induction 1 and 2, respectively (both comparisons were statistically significant).

MH was achieved in 31% (OCTAVE 1) and 28% (OCTAVE 2) in tofacitinib versus 16% and 12% in those receiving placebo (p<0.001).

In both induction trials, subgroup analysis showed no significant differences in the efficacy of TOF over placebo for ethnic origin, previous experience to anti-TNFα and concomitant use of aminosalicylates. 40, 41 At all visits, patients receiving TOF had larger improvement in partial Mayo score compared to placebo with significant reductions in stool frequency. 42

**Maintenance of Remission and Mucosal Healing**

A total of 593 patients from the OCTAVE Induction 1 or 2 trial who achieved clinical response at the end of 8 weeks with TOF 10 mg twice daily were re-randomized, in a 1:1:1 ratio into OCTAVE Sustain. These patients received maintenance therapy with tofacitinib 5 or 10 mg twice daily or placebo for 52 weeks. In this trial, 30% of the participants were in remission upon entry. The primary endpoint of
<table>
<thead>
<tr>
<th>Trial/Year</th>
<th>Phase</th>
<th>Arms</th>
<th>Size</th>
<th>Description</th>
<th>Selected Primary Endpoints</th>
<th>Selected Secondary Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Clinical Remission (8 weeks) % (p)</td>
<td>Clinical Remission (52 weeks) % (p)</td>
</tr>
<tr>
<td>Sandborn et al, 2012 (38)</td>
<td>II</td>
<td>Placebo</td>
<td>48</td>
<td>Placebo vs Tofacitinib</td>
<td>10% (p=0.76)</td>
<td>31% (p=0.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.5 mg BID</td>
<td>31</td>
<td></td>
<td>13% (p=0.01)</td>
<td>33% (p&lt;0.001)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 mg BID</td>
<td>33</td>
<td></td>
<td>15% (p&lt;0.001)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg BID</td>
<td>33</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 mg BID</td>
<td>49</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sandborn et al, 2017 [OCTAVE Induction 1] (40)</td>
<td>III</td>
<td>Placebo</td>
<td>122</td>
<td>Placebo vs Tofacitinib</td>
<td>8.2%</td>
<td>43.8% (N/A)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg BID</td>
<td>476</td>
<td></td>
<td>18.5% (p=0.007)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 mg BID</td>
<td>16</td>
<td></td>
<td>43.8% (N/A)</td>
<td></td>
</tr>
<tr>
<td>Sandborn et al, 2017 [OCTAVE Induction 2] (40)</td>
<td>III</td>
<td>Placebo</td>
<td>112</td>
<td>Placebo vs Tofacitinib</td>
<td>3.6%</td>
<td>50.0% (N/A)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg BID</td>
<td>429</td>
<td></td>
<td>16.6% (p&lt;0.001)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>15 mg BID</td>
<td>6</td>
<td></td>
<td>50.0% (N/A)</td>
<td></td>
</tr>
<tr>
<td>Sandborn et al, 2017 [OCTAVE Sustain] (40)</td>
<td>III</td>
<td>Placebo</td>
<td>198</td>
<td>Placebo vs Tofacitinib</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 mg BID</td>
<td>198</td>
<td></td>
<td>11.1% (p&lt;0.001)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 mg BID</td>
<td>197</td>
<td></td>
<td>34.3% (p&lt;0.001)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40.6% (p&lt;0.001)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BID, twice daily; N/A, not applicable.
OCTAVE Sustain was remission at 52 weeks. Key secondary endpoints were the achievement of MH at 52 weeks and of sustained glucocorticoid-free remission defined as glucocorticoid-free remission at 24 and 52 weeks. At 52 weeks, 34% of the 5 mg tofacitinib group, 41% in the tofacitinib 10 mg group, and 11% in the placebo group were in remission. As high as 37% in the patients receiving tofacitinib 5 mg, 46% of the tofacitinib receiving 10 mg, and in 13% of those receiving placebo had achieved MH. With regard to the other key efficacy endpoints, sustained and glucocorticoid-free remission were achieved by 35% and 47% of the 5-mg and 10-mg tofacitinib treatment arms as compared with the placebo arm, respectively (5%, p <0.001 for both comparisons). In subsequent subgroup analysis, no significant differences in efficacy of tofacitinib over placebo with regard to patients’ race and concomitant use of aminosalicylates were noted. In addition, irrespective of the tofacitinib dose received or anti-TNFα failure status, patients who entered the trial in remission were more likely to remain in remission or MH at week 52, compared to those who had not achieved remission after induction. All visits, patients receiving tofacitinib had better improvements in the partial Mayo score as compared to those receiving placebo (p < 0.001 for all comparisons).

**Recapturing Response**

**Loss of Response Secondary to Treatment Interruption**

The effect of tofacitinib in recapturing response after treatment interruption was studied in a subpopulation of 101 patients entered into the OCTAVE Open trial. These patients had achieved clinical response with tofacitinib 10 mg twice daily in the OCTAVE Induction trials, but experienced treatment failure – loss of response – in the maintenance study after being randomized to receive placebo. Treatment failure was defined as increase ≥3 points from OCTAVE Sustain baseline total Mayo score plus increase in rectal bleeding subscore and endoscopic subscore ≥1 point and absolute endoscopic subscore ≥2 points after ≥8 weeks of maintenance therapy. All of these patients received tofacitinib 10mg twice daily in the OLE study. Study outcomes included clinical response, MH, and remission at months 2 and 12 of OCTAVE Open. At month 2, 76%, 55%, and 40% of the subpopulation achieved clinical response, MH and clinical remission, respectively. Based on their findings, Panes et al suggested that in tofacitinib responders who lost response secondary to treatment interruption...
retreatment with 10 mg twice daily, recaptures response in approximately three-quarters of patients within 2 months and sustains the response up to 1 year.  

Loss of Response Secondary to Dose Reduction
Tofacitinib to recapture response after dose reduction was investigated in a subpopulation of 58 patients who had initially responded to tofacitinib in the OCTAVE Induction trials but lost response in the maintenance study after being allocated to tofacitinib 5 mg twice daily. All of these patients were treated with tofacitinib 10 mg twice daily in the OLE study. Study outcomes included clinical response, MH, and remission at months 2 and 12. At month 2, 58.6%, 41.4%, and 34.5% of the patients achieved clinical response, MH, and remission, respectively. Similar findings were identified at 12 months in these key outcomes (68.8%, 60.4%, and 52% for clinical response, MH, and remission, respectively). Based on these data, Sands et al suggested that in tofacitinib responders who lost response secondary to dose reduction for maintenance, retreatment with 10 mg twice daily recaptures response for most patients within 2 months following dose escalation.  

Induction of Response in Non-Responders to the Initial 8-Week Course (Delayed Response)
The efficacy of tofacitinib in inducing response in patients who failed to respond to an initial 8-week of tofacitinib 10 mg twice daily was investigated in 295 patients from both OCTAVE Induction trials. All of these patients continued to receive tofacitinib 10 mg twice daily in the OLE study. Study outcomes included clinical response, MH, and clinical remission evaluated at months 2, 12, 24, and 36. At month 2, clinical response was observed in 51% of the subpopulation, with 72%, 61%, and 54% of the patients preserving response at 12, 24, and 36 months, respectively. Approximately half of the patients were in remission (49%, 45% and 45% at months 2, 12, 24, and 36, respectively), while MH was observed in the majority of patients (57%, 53%, and 51% at months 2, 12, 24, and 36, respectively) at any time-point after the first year of treatment. Similar trends over time were observed when prior failure to anti-TNFα was taken into consideration. Based on these findings, Rubin et al suggested that a substantial proportion of non-responders to the initial 8-week course of tofacitinib at dose 10 mg twice daily respond to an extended induction course and achieved response lasting up to 3 years, irrespective of patients’ previous failure status to anti-TNFα.  

Improvement of Remission After 52 Weeks of Response
The efficacy of tofacitinib in achieving remission after prolonged response was investigated in a subpopulation of 82 patients who had responded to tofacitinib at 52 weeks. Of the 82 patients, 1 entered the Sustain trial in error, 18 were randomized to receive placebo, 28 to tofacitinib 5 mg twice daily and 35 to tofacitinib 10 mg twice daily. All of these patients received tofacitinib 10 mg twice daily in the OCTAVE Open trial. Efficacy endpoints included clinical response, MH, and clinical remission at months 2, 12, 24, and 36. At 24 months, clinical response was maintained by 70% of the patients. No difference in clinical response was observed between participants who had previously failed (65%) or not failed (73%) anti-TNFα therapy. By month 2, remission rates were improved in the majority of patients regardless of anti-TNFα failure status (59% [48/82], 61% [23/38] and 57% [25/44] of the total number of patients and of those with and without failure to anti-TNFα, respectively). Similar trends were observed with regard to MH over time. Based on these data, tofacitinib 10 mg twice daily was shown to be effective in inducing remission in UC patients with prolonged response who had not achieved remission, regardless of their previous failure status to anti-TNFα.  

Maintenance of Remission Following Dose Reduction
The maintenance of remission for patients following a dose reduction in tofacitinib was investigated in a cohort of 76 patients from the SUSTAIN trial. All of these patients were in remission at 52 weeks on tofacitinib 10 mg twice daily and subsequently received tofacitinib 5 mg twice daily in the OPEN study. Based on the time-point in the SUSTAIN trial that remission state was achieved, the patients were further divided into 3 groups. Patients who were in remission at baseline in the SUSTAIN trial were included in the first group (remission ≥12 months pre-dose reduction); patients in remission at 24 weeks were included in the second group (remission 6–12 months pre-dose reduction); and patients in remission at 52 weeks were included in the third group (remission <6 months pre-dose reduction). Overall, rates for maintenance of remission were 82% at 12 months and 76% at 24 months in the OPEN study. Among the 3 different groups, the remission rates at 12 months were 91% for the first group, 82% for the second group, and 71% for the third group. This data suggest that the majority of UC patients who achieved stable remission with tofacitinib 10 mg twice daily and dose reduced to 5 mg twice daily maintained remission for up to 24 months
following the dose reduction, although the authors highlighted that this benefit may be greater in those patients who are in remission for ≥6 months prior to dose reduction.

Effect on Health-Related Quality of Life (HRQoL)
The effect of tofacitinib on HRQoL was investigated across the single phase II, the two OCTAVE Induction and the single OCTAVE Sustain trials. This was performed using the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ) in the phase II trial, and both the IBDQ and generic SF-36v2® Health Survey (SF-36) in the other trials.

In the phase II trial, IBDQ was completed at baseline (day 1), with total scores being similar across all treatment groups, ranging from 123.2 to 134.5.52 At week 8, mean IBDQ total scores had dose-proportionally improved compared to baseline measurements across all five treatment groups (week 8 range 149.6–175.4), with the improvement being significantly higher over placebo (p = 0.001) only for those patients who received tofacitinib 15 mg twice daily. Patients in endoscopic remission were found to have significantly higher IBDQ scores than those who had not achieved endoscopic remission.

In the two induction trials, IBDQ was completed at baseline (day 1), week 4, and week 8, whereas SF-36 was completed at baseline and week 8.53 At week 8, mean changes from baseline IBDQ were higher in those patients treated with tofacitinib 10 mg twice daily (40.7 and 44.6) compared to those receiving placebo (21.0 and 25.0, p < 0.0001). Similar findings were observed for SF-36, which measure mean changes from baseline in Physical and Mental Component Summaries (PCS/MCS). The OCTAVE induction 1 and 2 trials show PCM 6.8 and 6.8, and MCS 6.8 and 7.6, respectively, for those patients receiving tofacitinib 10 mg vs PCS 2.5 and 4.6 and MCS 3.5 and 4.4 for those receiving placebo (p < 0.01). In both trials, HRQoL was found to be significantly correlated with clinical remission and mucosal healing. In the Sustain trial, IBDQ was completed at weeks 8, 16, 24, 32, 40, and 52, whereas SF-36 was completed at weeks 24 and 52. At week 52, changes from baseline in IBDQ total scores were maintained with tofacitinib (3.7 for those receiving 5 mg twice daily and 4.8 for those at 10 mg) as compared to placebo (–26.5, p < 0.0001). The conclusion for the observed changes in the PCS (0, 0.3 for tofacitinib 5 and 10 mg twice daily vs –5.2 for placebo, p<0.0001) and MCS subscores (−1, 0.1 for tofacitinib 5 and 10 mg vs −6.7 for placebo, p<0.0001) of SF-36 was similar.

Overall, tofacitinib was found to result in significant improvements in HRQoL compared to placebo, and this was strongly related to clinical and endoscopic remission. Similar conclusions were reached when data from the induction and maintenance trials were re-analyzed, using the comparatively more stringent IBDQ criteria for remission (total score ≥190) and response (≥30-point increase from baseline).50

Real-World Experience
The real-world experience of tofacitinib in the management of active UC derives from three retrospective studies from tertiary referral centers across USA and France (Table 2). Weisshof et al describe their experience of tofacitinib in a cohort of 58 patients with inflammatory bowel disease with UC, 4 with Crohn’s disease, 1 with

Table 2 Real-World Studies

<table>
<thead>
<tr>
<th>Number</th>
<th>Previous Biologics</th>
<th>Dose</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weisshof et al (51)</td>
<td>58 patients (53 with UC)</td>
<td>93% failed TNFi 81% failed VDZ</td>
<td>60% (n=30) received 10 mg BID 38% (n=22) received 5 mg BID 2% (n=1) received 11mg ER OD</td>
</tr>
<tr>
<td>Ungaro et al (52)</td>
<td>123 patients with UC</td>
<td>28.5% biologic naïve 40.7% failed both TNFi &amp; VDZ</td>
<td>All received 10mg BID</td>
</tr>
<tr>
<td>Lain-Mehiri et al (53)</td>
<td>37 patients with UC</td>
<td>All failed TNFi 97% failed VDZ</td>
<td>All received 10 mg BID</td>
</tr>
</tbody>
</table>
The majority (93%) of the patients had previously failed treatment with anti-TNFα and 81% had failed treatment with vedolizumab, thus constituting a highly medically refractory population. Tofacitinib dose was selected based on symptom severity, with 35/58 (60%) receiving tofacitinib 10 mg twice daily, 22/58 (38%) receiving tofacitinib 5 mg twice daily, and one patient receiving an extended-release tofacitinib 10 mg once daily. Of those receiving 10 mg twice daily, 7 patients started on tofacitinib 15 mg twice daily for severe disease before reducing to 10 mg twice daily within 2–4 weeks due to limited efficacy. Of those receiving 5 mg twice daily, 10 patients were escalated to 10 mg twice daily, with 8 achieving clinical response. All patients received tofacitinib for at least 8 weeks and clinical response (defined as symptomatic improvement from baseline) was assessed at 8, 26, and 52 weeks. After 8 weeks of treatment, 21 patients (36%) achieved a clinical response and 19 (33%) achieved clinical remission, corresponding to an overall response rate of 69%. The proportion of patients still being maintained on tofacitinib at 3, 6, and 12 months was 69%, 55%, and 51%, respectively. Corticosteroid-free remission occurred in 26%, 21%, and 27% of the patients at 8, 26, and 52 weeks, respectively.

In another cohort study from six centers in the USA, Ungaro et al retrospectively reviewed the data of 123 patients with active UC who received tofacitinib 10 mg twice daily for at least 8 weeks. A minority (28.5%) of patients were biologic naïve, whilst 40.7% had been exposed to both anti-TNFα and VDZ. Clinical response (defined as >50% reduction in symptoms) and clinical remission (defined as absence of symptoms) was assessed at week 8 and week 16, and endoscopic healing (defined as Mayo endoscopic score ≤1 or absence of erosions/ulcerations) was assessed within 6 months of initiating tofacitinib. Ninety-six patients completed 8 weeks of treatment with an overall clinical response of 60.8% and clinical remission of 13.5%. At week 16, 74 patients remained on tofacitinib, with a clinical response of 55.4% and clinical remission of 48.6%. The majority of patients (64.9%, n = 57) achieved endoscopic healing at 6 months. Subgroup analysis showed that those patients naïve to biologics responded significantly better to tofacitinib than those with previous exposure. The patient’s naïve status (adjusted odds ratio [aOR] 5.50, 95% CI 1.71–17.65), the concomitant use of corticosteroids (aOR 0.25, 95% CI 0.07–0.83) and male gender (adjusted hazard ratio 0.25, 95% CI 0.08–0.83) were found to be independently associated with clinical response at week 8.

A French multi-center retrospective study included 37 patients with medically refractory UC treated with tofacitinib 10 mg twice daily for at least 24 weeks. All patients had previously been treated with a TNFi and 97% with VDZ. The primary endpoint was colectomy-free survival rate at week 24 and was achieved in 77% of the patients. Survival without drug interruption was seen in 25 patients (62.6%, 44.3–76.4%) at week 24 and 9 patients at week 48 (58.2%, 39.2–73.1%). At 24 weeks, clinical response was achieved by 41% of the patients, with 32% being in a corticosteroid-free clinical remission status.

Collectively, these three studies show that tofacitinib is an effective treatment in the management of refractory UC in a real-world setting.

### Comparative Efficacy of Tofacitinib vs Biological Therapies

In the absence of head-to-head trials, evidence of the comparative efficacy of tofacitinib and biological therapies is based on indirect evidence from four network meta-analyses (NMA). These all compared tofacitinib with antiTNFα (infliximab, adalimumab, golimumab) and anti-integrins (VDZ), and all synthesized data from randomized controlled phase II and/or III trials. Three out of four NMAs used clinical (response and remission) and endoscopic (MH) efficacy endpoints as outcomes, whereas one used HRQoL.

Singh and Bonovas undertook their analyses of clinical and endoscopic endpoints in anti-TNFα naïve cohorts by basing their probabilities of each treatment being superior. The authors concluded that infliximab and VDZ may be superior for the induction of clinical response, remission, and MH. Trigo-Vicente et al reached similar conclusions. However, the addition of ozanimod (a sphingosine-1-phosphate receptor agonist) and etrolizumab (an anti-adhesion molecule antibody) in their analysis showed that ozanimod may be better than infliximab for the achievement of MH. In contrast, for patients who were anti-TNFα experienced, tofacitinib was ranked higher for the induction of remission and of MH compared to the other available treatments. For the maintenance of remission, no indirect comparisons were performed for anti-TNFα experienced patients. However, in anti-TNFα naïve patients, Trigo-Valente et al found that tofacitinib had the highest probability of being the best treatment in...
the maintenance of remission, sustained remission and for MH.

With regard to the impact of different therapies on HRQoL, at induction, Paschos et al found that all of the compared therapies significantly improved both generic and disease-specific HRQL scores compared to placebo. However, the improvement was clinically meaningful only for infliximab (18.58; 95% CI 13.19–23.97) and VDZ (18.00; 95% CI 11.08–24.92). For maintenance, VDZ, tofacitinib, and adalimumab were found to maintain the improvement in HRQL.

**Safety of Tofacitinib in UC**

The first centralized evaluation of the short- and long-term safety profile of tofacitinib in the management UC was recently published. The report was focused on specific adverse events (AEs), including herpes zoster (HZ), opportunistic infections (OIs), malignancies, non-melanoma skin cancers (NMSC), major adverse cardiovascular events (MACE), and gastrointestinal perforations. The safety data were collated from the four aforementioned market-authorizing trials, including 1157 patients over a 4.4-year period (1612.8 patient-years of exposure). They were analyzed as 3 cohorts: the induction cohort, which included data from patients randomized to placebo or tofacitinib from the dose-finding phase II and the two phase III induction trials; the maintenance cohort, that included data from patients from the Sustain trial; and the laboratory cohort that included data from patients from the induction and the sustain cohort who were evaluated for changes over time in laboratory parameters. Serious adverse events (SAEs) were defined as any treated infections that required parenteral antimicrobial therapy, hospitalization, or fulfilled criteria for SAEs, were rarely observed (IR: 2.0; 95% CI: 1.4–2.8). However, there were four types of SI that were reported more than once including appendicitis, herpes zoster infection (HZ), anal abscess, and *Clostridium difficile* infection. None of these infections were fatal.

In the maintenance cohort, the incidence ratio for HZ was found to be increased in UC, with greater values being observed in those patients receiving tofacitinib 10 mg compared to those receiving tofacitinib 5 mg or placebo. This finding signified a dose-proportional increase of the associated risk for HZ. In the overall cohort, there were recorded 18 cases of HZ, with older age, prior anti-TNFα failure, and non-white (mainly Asians) race being independently associated with an increased risk for developing HZ. However, in most cases, HZ infection was cutaneous over 1 or 2 adjacent dermatomes and did not require permanent discontinuation of tofacitinib. A more detailed analysis of HZ events in the UC program has been reported by Winthrop et al. In this study, based on their previous experience in RA, the authors suggested that vaccination against HZ could be a possible preventive strategy for non-exposed UC patients; however, in the absence of robust data from UC, vaccination is not currently recommended. An ongoing randomized controlled trial evaluating the safety and immunogenicity of HZ vaccine across a variety of immune-mediated disorders, including patients with UC (VERVE trial, NCT02538341), is expected to provide some more definitive results on this.

During the observation period in the OCTAVE trials, four deaths were recorded in the overall population, with 3 out of 4 cases being secondary to malignancies (hepatic angiosarcoma, acute myeloid leukemia, and cholangiocarcinoma). In the overall cohort, 22 patients were diagnosed with malignancy, with 50% of the cases having NMSC. The majority (18 out of 22) of patients were experienced with anti-TNFα and thiopurines, whereas 6 out of the 11 with NMSC had previous history of NMSC. Overall, malignancies were rarely observed.

With regard to other adverse events, 3 cases of colonic perforations and 4 MACEs (hemorrhagic stroke, aortic dissection, acute coronary syndrome, and myocardial
infarction) were recorded in the study. Nearly all of the involved (5/7) patients had multiple risk factors that may have contributed to the development of these complications. In particular, 2 out of the 3 cases of perforation occurred in patients with a background of active UC inflammation or Epstein–Barr virus intestinal lymphoma who were recently prescribed corticosteroids and underwent an endoscopic procedure, whereas the third case occurred in a patient who developed appendicitis and received concomitant nonsteroidal anti-inflammatory drugs. Likewise, 3 out of 4 with MACE had ≥4 predisposing cardiovascular risk factors. However, other than a case of aortic dissection that resulted in death, all of the other MACE were resolved after temporary or permanent discontinuation of TOF.

No clinically meaningful changes were observed in various laboratory parameters, including the low-density lipoprotein/high-density lipoprotein ratio, hemoglobin, absolute lymphocyte count, and creatine kinase. No additional or unexpected safety signals were identified, supporting the long-term use of tofacitinib in patients with moderately to severely active UC.

**Safety of Tofacitinib vs Biological Therapies**

As with comparisons of the efficacy between tofacitinib and biological therapy, comparative safety data are derived indirectly from NMAs. Trigo-Vicente et al showed that all comparative treatments were more likely to cause SAEs than placebo and that all therapies had similar probabilities of causing SAEs. With regards to opportunistic infections, tofacitinib had the highest rate (although most were minor), whilst golimumab and vedolizumab also showed increased rates, and infliximab and adalimumab did not show a statistically significant increased rate compared to placebo.

**Safety of Tofacitinib in Specific Populations**

The safety of tofacitinib in children, pregnant women, and elder patients has not been directly studied in UC. However, Mahadevan et al recently reported pregnancy and infant outcomes from patients with both maternal and paternal prenatal exposure to tofacitinib who participated in the five aforementioned UC clinical trials. Of the 1157 patients enrolled in these studies, 301 were women of childbearing age with 11 cases of maternal exposure and 14 cases of paternal exposure identified. In total, they reported 15 healthy newborns, no fetal or neonatal deaths, no congenital malformations, 2 spontaneous abortions, and 2 medical terminations. These findings appear similar to those reported from other clinical study populations and the general population. Nevertheless, more data are clearly needed to evaluate safety in this particular setting.

**Safety of Tofacitinib in Other Disease Populations**

The incidence ratio of adverse events of special interest in the tofacitinib UC program was generally consistent with those reported in the RA program. However, a post-marketing study (A3921133) in RA found an increased incidence of pulmonary embolism among patients over 50 years with more than 1 cardiovascular factor receiving the 10 mg twice daily dose. This finding has led regulatory authorities to restrict the use of tofacitinib in patients with an increased risk for thromboembolism, which includes heart failure, cancer, thrombophilia, previous history of thromboembolic episodes, patients receiving hormonal contraceptives or hormone replacement therapy and those undergoing major surgery. An ongoing safety trial in RA and future post-marketing studies in UC are expected to shed more light into this relationship.

**Potential Place in UC Pharmacotherapy**

Tofacitinib is the first oral JAK inhibitor that has been approved by the EMA and the FDA for the management of adult patients with moderately to severely active UC. The American College of Gastroenterology (ACG) has recently positioned tofacitinib in the therapeutic algorithm of UC either as first-line therapy for moderate-to-severely active disease or as second-line therapy in those who have failed anti-TNFα. In addition, the real-world studies described above show that tofacitinib can be used effectively as third-line therapy in patients who have failed both anti-TNFα and vedolizumab. Although the NMAs suggest tofacitinib may be less effective than anti-TNFα as a first-line therapy and more effective as a second-line therapy, more substantial evidence is needed to inform selection preference.
As tofacitinib is the latest therapy to be approved for UC, its current use mostly assumes that of salvage therapy. However, compared to the available biologics (infliximab, adalimumab, golimumab, and VDZ), tofacitinib has several potentially favorable characteristics that could lead to its preferential selection. Firstly, it is orally administered which could improve therapy adherence and quality of life in patients averse to the requirement for long-term injections or infusions. Its pharmacokinetic profile, characterized by rapid absorption, metabolism, and clearance, is advantageous in situations where rapid onset of action (e.g., acute severe colitis) or elimination of the drug (e.g., infection, surgery, or pregnancy) is required. Importantly, tofacitinib is a small synthetic molecule that would not induce an immunogenic response. Therefore, unlike the anti-TNFα agents, the anti-TNFα in particular, there is no risk of loss of response due to antibody formation against the drug, negating the need for combination therapy with an immunomodulator to prevent this. In addition, tofacitinib would be expected to have lower costs than the biologics, given it is a small molecule with less elaborate production and will therefore have a higher cost-effectiveness ratio.

Future Directions
The evidence on the efficacy and safety of tofacitinib for the management of UC mainly arises from clinical trials and pertain to restricted populations. Post-marketing studies are needed to expand clinicians’ experience on the efficacy and safety of tofacitinib in real-world populations, including specific groups excluded from the licensing trials (e.g., elders and children), and to address the potential thromboembolic risk highlighted in the RA population.

With the approval of tofacitinib for the management of moderately-to-severely active UC, the available therapeutic options have increased, creating an issue with selection. Current evidence is insufficient to support preferential selection amongst the available therapeutic options and direct head-to-head comparison trials are necessary to address this issue.

Conclusion
Tofacitinib is a valuable addition to the therapeutic armamentarium for managing UC. The OCTAVE trials have shown that tofacitinib is effective for the management of moderately-to-severely active UC with a good overall tolerance, although the potential risk of thromboembolism seen in the RA population needs further evaluation. Current recommendations issued by the ACG have positioned tofacitinib alongside the established biologic agents for both induction and maintenance of remission of moderate-to-severely active UC. Although tofacitinib possesses several favorable characteristics (e.g., oral administration, lack of immunogenicity, rapid action, and clearance), the exact place against more established biological therapies will become more evident as clinical experience with this novel agent improves.

Disclosure
Dr Argyriou has received a grant from the Hellenic Society of Gastroenterology for post-doctoral research at Nottingham Digestive Diseases Centre (protocol number: 7406/20-12-2016). Dr Varyani has received speaker honoraria from Takeda Pharmaceuticals and has received educational support from Takeda and Abbvie. Dr Moran has received educational support from Abbvie, Janssen, NAPP, Takeda Pharmaceuticals, Merck Sharp & Dohme Ltd, Ferring, and Dr Falk. He has received speaker honoraria from Merck Sharp & Dohme Ltd, Abbvie, Janssen, Ferring and Takeda Pharmaceuticals. He attended advisory boards for Abbvie, Takeda Pharmaceuticals, Janssen, Medtronic, Phebra Pharmaceuticals, Servertus Associates Ltd and Dr Falk. The authors report no other conflicts of interest in this work.

References


